PMS43 Cost-Effectiveness of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in the Treatment of Severe Active RA
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1398
https://www.valueinhealthjournal.com/article/S1098-3015(12)03111-7/fulltext
Title :
PMS43 Cost-Effectiveness of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in the Treatment of Severe Active RA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03111-7&doi=10.1016/j.jval.2012.08.1398
First page :
A447
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
898